What Bivalirudin is
Bivalirudin is a peptide-based direct thrombin inhibitor used in approved anticoagulation settings.
Bivalirudin is grouped under Approved / Clinical on PeptideFactCheck because it proves that practical peptide medicine includes high-stakes hospital drugs, not just performance and longevity topics.
The useful starting point is to separate the molecule itself from the internet story around it. It proves that practical peptide medicine includes high-stakes hospital drugs, not just performance and longevity topics.
Why people keep looking it up
It proves that practical peptide medicine includes high-stakes hospital drugs, not just performance and longevity topics.
Bivalirudin is a peptide-based direct thrombin inhibitor used in approved anticoagulation settings.
Bivalirudin tends to stay in the conversation because it touches a familiar public theme: direct thrombin inhibitor, anticoagulation, and peptide medicine. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Approved peptide medicine with direct human and label support.
Human trials and official labeling support specific approved uses.
Mechanism follows direct thrombin inhibition and coagulation biology.
Why this page carries the current tier: Approved peptide medicine with direct human and label support.
The current seed trail for Bivalirudin is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
This is a high-consequence anticoagulant context and should not be framed casually.
FDA-approved bivalirudin products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Bivalirudin. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Bivalirudin is CID 16129704. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 16129704
- Formula
- C98H138N24O33
- Molecular weight
- 2180.3
- InChIKey
- OIRCOABEOLEUMC-GEJPAHFPSA-N
Matched synonyms include Bivalirudin, 128270-60-0, bivalirudina, bivalirudine, bivalirudinum, BG-8967, BG8967, L-Leucine, D-phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-alpha-aspartyl-L-phenylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyrosyl-.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Bivalirudin returns 92 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Bivalirudin returns 2170 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- bivalirudin
- Generic names
- BIVALIRUDIN
- Routes
- INTRAVENOUS
- Application numbers
- NDA020873
Indications and usage. 1 INDICATIONS AND USAGE Bivalirudin for injection is indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Bivalirudin for injection is a direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous corona...
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS • Bleeding Events: Bivalirudin increases the risk of bleeding. ( 5.1 , 6.1 , 12.2 ) • Acute Stent Thrombosis: Increased incidence of acute stent thrombosis in STEMI patients undergoing primary PCI. ( 2.1 , 5.2 ) • Thrombotic Risk with Coronary Artery Brachytherapy: An increased risk of thrombus formation, including fatal outcomes, in gamma brachytherapy. ( 5.3 ) 5.1 Bleeding Events Bivalir...
Contraindications. 4 CONTRAINDICATIONS Bivalirudin is contraindicated in patients with: • Active major bleeding; • Hypersensitivity (e.g., anaphylaxis) to bivalirudin or its components [see Adverse Reactions (6.1) ] . • Active major bleeding ( 4 ) • Hypersensitivity to bivalirudin or its components ( 4 )
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.